ANGLE plc (ANPCF)
| Previous Close | 0.1964 |
| Open | 0.1610 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1610 - 0.1610 |
| 52 Week Range | 0.1320 - 0.5200 |
| Volume | |
| Avg. Volume | 19 |
| Market Cap | 67.685M |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cancer patients over two and a half years using the ...
- ACCESSWIRE
Angle PLC Announces New Commercial Agreement with Large Pharma
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative ...
- ACCESSWIRE
Angle PLC Announces New Commercial Agreement with AstraZeneca
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative ...
